BULLETIN V2025-4072
BIOSYENT INC. ("RX")
BULLETIN TYPE: Normal Course Issuer Bid
BULLETIN DATE: December 16, 2025
TSX Venture Tier 2 Company
TSX Venture Exchange has been advised by the Company that pursuant to a Notice of Intention to make a Normal Course Issuer Bid dated December 11, 2025, it may repurchase for cancellation, up to 800,000 common shares in its own capital stock. The purchases are to be made through the facilities of TSX Venture Exchange or other recognized marketplaces during the period December 19, 2025 to December 18, 2026. Purchases pursuant to the bid will be made by Raymond James Ltd. on behalf of the Company.
_______________________________________
|
|
